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1. Introduction to Intellectual Property Rights 
This paper starts with a simple and brief introduction of Intellectual Property Rights. 
Intellectual property gives certain right  to some individual to exclude others from the 
use of specific intangible creations/innovations for a certain period of time. These 
creations take the form of tangible products. The Law gives protection to the intangible 
creations like ideas, technical solutions. This impl es that the owner of a patent can 
prevent the manufacture, use or sale of the patented product in the countries where the 
patent has been registered. This explains why intellectual property rights may have a 
direct and substantial impact on industry and trade 
 
Intellectual property rights include the following categories:  
• Copyright and related rights 
•  Trademarks 
•  Geographical indications 
•  Industrial designs 
•  Patents 
•  Layout designs of integrated circuits 
•  Trade secrets 
•  Breeders’ rights 
•  Utility models.  
 
      The relevance and importance of different categories of IPRs varies from country                          
to country. It depends upon: 
• The level of technological and economic development,  
• Different degrees of R&D intensity  
• Rate and nature of innovative activities  
• Type of goods and services it produces.  
Technological developments which can actually be cat gorized as `inventions' are rather 
rare in developing countries; In most cases, patents granted there belong to foreign 
companies and only a few to nationals.  
 
2. TRIPS-A New Regime 
General Agreement on Tariffs and Trade (GATT ) negotiations on 1 January 1995 
introduced the  New Intellectual Property Right (IPR) regime under Trade Related 
Aspects of Intellectual Property Rights (TRIPS)  . It required the developing countries 
to amend their existing IPR regimes and adopt ones similar to those prevailing in the 
industrialized countries. The TRIPS Agreement requires the member countries to 
recognize seven forms of IPRs; i.e. Copyrights, Trademarks, Geographical 
Indications, Industrial Designs, Patents, Layout designs of integrated circuits, and 
Trade Secrets. IPR included the Breeders’ Rights and Utility models but the new regime 
under TRIPS excludes them. 
  
TRIPS permits developing countries such as India a transition period of five years to 
implement the provisions of TRIPS. In addition, if a country did not provide product 
patent protection in any field when TRIPS came intoforce, then additional 5 years is also 
given to them. Even though the Developing countries such as India had time till 1 
January 2005 to introduce full product patents protection for pharmaceuticals and 




product patent applications in the fields of pharmaceuticals) and ‘exclusive marketing 
rights’ provision from 1 January 1995.  
 
The main provisions relating to Patents in TRIPS are as follows: 
 Patents shall be available for any invention, whether a product or process, in all 
fields of technology without discrimination, where those inventions meet the 
standard substantive criteria for patentability —novelty, inventive step and 
industrial applicability. 
 The available term of protection must expire no earli r than 20 years from the 
date of filing the patent application. 
 The Patent Owner has the Right to prevent unauthorized persons from using the 
patented process and making, using, offering for sale, or importing the patented 
product or a product obtained directly by the patented process. 
 The Agreement allows limited exceptions to be made by Members provided that 
such exceptions do not unreasonably conflict with a normal exploitation of the 
patent. One such case is the ‘Bolar Provision’,in which the generic producers of 
patented products, are permitted without authorization and prior to the expiry of 
the patent term, to use a patented invention for research purposes, so that they can 
seek regulatory approval from public health authorities for the marketing of their 
generic version as soon as the patent expires. 
 The Agreement also allows Members to authorize use by third parties 
(compulsory licenses) or for public non-commercial purposes (government use) 
without the authorization of the patent owner. 
 In case of Infringements, the burden of proof will be on the alleged infringer 
rather than on the right holder. * 
 
3. TRIPS-developed vs. developing countries 
Developed countries supported the New IPR regime under TRIPS because, 
Technological advancements and developments in developing countries was going at a 
fast pace mainly because of technology diffusion and spillovers from the developed 
countries.This was attributed to the open technological and scientific system. So there 
was a relative loss of competitiveness. Moreover, the developed countries who were more 
into R&D saw a steady rise in the expenditure incurred on R&D purposes; but 
comparatively less revenue earned due to weaker protecti n of IPR as in the developing 
countries. So,I f they could get a stronger protection, it would recoup their costs and give 
them an incentive to innovate further. 
 
The main point of argument of the developing countries with regard to the weak 
protection of IPRs in chemicals, foodstuffs and pharmaceuticals can be attributed to the 
fact that it serves as an instrument to avoid restrictions in “the  supply of essential 
products” , with the implicit assumption being that technological innovation should be 
considered as a public good and not a private capital good. Other points of concern 
included the exploitation of market power by foreign companies - wiping out of the 
domestic firms by MNCs and the impact of protection on domestic prices mainly leading 
to a spiraling of prices. 
                                                




In this regard, the words of Indira Gandhi , spoken at the World Health Assembly in 
May 1982 is worth quoting: 
 “The idea of a better-ordered world is one in which medical discoveries will be free of 
patents and there will be no profiteering from life and death.” 
UNCTAD also recommended in 1975 that pharmaceuticals should be made available to 
developing countries at a marginal cost. This meant that extensive R&D to be performed 
for new drugs, which are tailored to the needs of developing countries, i.e., which 
addresses the general tropical diseases of the developing countries and attacks the 
population in masses.  
 
Yet, some of the possible reasons for the developing countries to accept the stronger IPR 
protection may be attributed to the following reasons:  
• Decreasing private capital flows to developing countries,  
• Negative experiences with the regulatory approach. 
• Ongoing “technological revolution”  
• Reasonable amount of respect for IPRs is fundamental for stimulating 
technological change.  
 
*The costs and benefits of strengthening the IPR system befalling a developing country 
can be discussed as under:  
            Among the COSTS are,  
• Administrative and enforcement costs associated with the reform, which are not 
trivial;  
• The increased royalty payments  
• The costs of economic displacement of “pirates”, which involves two social 
costs, namely displacing/wiping out of the companies/pirate firm and the rise in 
unemployment level (as the factors of production displaced from the affected 
industry would not find employment in the other sectors of the economy.);          
• Loss in consumer surplus generated by the anticompetitive aspect of such 
measures (there would be significant increase in prices dueto increased market 
power which enables the seller to reduce output and r ise prices, and driving a 
larger wedge between price and marginal cost , increasing static welfare losses. 
Evidence suggests that patents “in most cases do not prevent imitation and thus 
may not slow down diffusion to any great extent”. IPRs may affect learning 
economies and increase entry barriers. Brand Loyalty will be a more effective 
barrier to entry under a strengthened IPR system). 
 
           The main BENEFITS are, 
• Cost savings derived from additional domestic R&D and the disclosure of new 
knowledge (the qualitative implications of IPRs, i.e. the degree to which they 
foster genuine innovation as opposed to mere imitation);  
• Positive contributions to global technological dynamism (inventors in the 
industrialized areas of the world may need some special incentive to concentrate 
their talents on products of special utility to under eveloped areas);  
• Benefits from additional technology transfers (technology owners do not have 
an incentive to transfer their proprietary knowledg to countries with weak IPR 
systems, in view of the potential for “piracy”);   
                                                
*  World Bank Discussion Papers (112)(2001) 
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• More capital formation in knowledge intensive sectors (composition of foreign 
direct investment will increase in the developing country)  
 
4. The India Patents Act 1970 
The Patent Regime in India can broadly be classified under the following three heads: 
 
• Patents and Designs Act of 1911, which effectively had a product patent regime 
in drugs and medicines. 
• After 1972, the Patents and Design Act, 1911 was replaced by the Patents Act, 
1970. Drug product patent protection was abolished and process patents came into 
being. India became a major producer and a source of low cost but high quality 
drugs for the entire world. 
• From 1 January 2005, post TRIPS, drug producer patent protection has again 
been introduced in India. 
 
With respect to process patents, the provisions related to ‘License of Rights’, 
“compulsory license”, “working of patent within 3 years of sealing date”, “burden of 
proof in case of patent infringement” further limited the scope of protection substantially. 
The abolition of pharmaceutical product patent protection in 1972 paved the way to 
achieve an independent Indian pharmaceutical industryGoing by the statistics, the Indian 
Patents Act was a ‘success’. The number of supplying firms increased from 2,237 
licensed drug manufacturers in 1969-70 to an estimated 16,000 producers in 1992-93. 
The production of drug formulations grew at an averg  annual rate of 14.4 percent 
between 1980-81 and 1992-93; the negative balance of trade in bulk drugs and drug 
formulation that prevailed throughout the 1970s and 1980s was turned into a trade 
surplus by 1990. * 
 
The period 1970-2004 saw a declining market share of Multi National Corporations 
(MNCs) in India. In 1970, Indian owned firms held a share of only 10-20 percent of the 
total pharmacy market, MNCs accounted for the remaining 80-90 percent. By 1980, 
Indian firms and MNCs had an equal share of about 50 percent; by 1993, Indian firms 
had raised their share to 61 percent and by 2004,the share of Indian firms has increased to 
75%. The relative decline of MNCs in the Indian pharm cy market has been attributed to 
various factors, in addition to the abolition of product patent protection through the 
Indian Patents Act.  
                                                







Market shares of MNCs and Indian Companies in the Pharmaceutical Industry 
 
Year Multi National 
Companies 
Indian Companies 
1952 38 62 
1970 68 32 
1978 60 40 
1980 50 50 
1991 40 60 
1998 32 68 
2004 23 77 
Source: , Chaudhuri Sudip Table 2.2: page-18 
 
The imitation and production of drugs protected by patents in other countries by reverse 
engineering was the key to success for Indian firms. This has been possible due to highly 
developed chemical infrastructure and good process skill of the Indian firms. Thus it was 
possible for Indian firms to introduce the copied brands in the Indian market soon after 
the world introduction of these drugs at affordable prices, thus making it a competitive 
market in the world. Moreover, The Indian Patent Acof 1970 providing only seven years 
of process patent protection for pharmaceuticals, and rigid price control of the 
government posed a huge opportunity for the domestic industry to produce generics. 
 
The transition of the Indian Pharmaceuticals Industry from an import dependant one in 
1950’s to a self sufficient supplier and exporter of high quality drugs at affordable prices 
can be attributed to the process patent regime. 
 
5. India’s Patent Policy and TRIPS 
The TRIPs Agreement came into effect on January 1, 1995 with the provision that India 
must have a regime that grants pharmaceutical product patents by 2005. Failure to meet 
TRIPs requirements would jeopardize India's market access rights and other benefits 
under the WTO.  
The philosophy of India’s Patent Act of 1970, supporting innovation as a public rather 
than private good, varied significantly from the framework being established under 
TRIPs. Though it covered the public interest angle, it also helped the growth of industry.  
The type of patent system that India established was clearly against the global IP regime 
promoted by the US. The main objection of the US is to the provision in India's patent law 
that allows for process but not product patents in the area of food, drug or medicine. This 
can be traced to the reason that the costs for developing a new drug/chemical entity(NCE) is 
very high and the costs for developing processes for manufacturing a new drug is low. So, 
without patents, it may be possible to imitate the new products thereby limiting the 
innovators ability to recoup the R&D costs. The United States terms the activities of India to 
find alternative processes by reverse engineering as “piracy”. According to the US, Indian 
firms are copying technology developed by advanced nations. This is leading to large-scale 
losses for the US. The Pharmaceutical industry in the US especially Phrma, the association 




Summary of Indian Patents Act, 1970 and TRIPS 2005 
 
Indian Patent Act TRIPS 
Only process, not product patents in food, 
chemicals and pharmaceuticals 
Process and product patents in almost all 
fields. 
Tenure of patents-14 years, 5-7 in 
chemicals, drugs 
Tenure of patents-20 years 
Compulsory licensing and license of right 
exercised 
Provision of compulsory licensing but no 
license of right. 
Government allowed to use patented 
invention to prevent scarcity in emergency. 
Very limited scope for governments to use 
patented inventions. 
 
These amendments in the Patent Act so as to comply with TRIPS may foster major 
changes in the Indian Pharmaceutical sector. Indian companies will not be legally able to 
produce generic versions of drugs currently protected by patents. Since India is a haven 
for generic production of drugs, there will certainly be a negative impact on the domestic 
growth and production. From the consumer point of view, some of the main impacts will 
be the unavailability of cheap generic drugs before th  20-year period of protection 
elapses and the generally higher prices of drugs. Generally increased protection implies 
increased R&D, but it necessarily does not imply preferential investment in medicines 
needed by the poor. 
 
6. The Pharmaceutical Sector in India  
The Indian Pharmaceutical industry is the pre-eminent sector in India, in terms of 
scientific and technological developments. It meets about 70% of India's demand for bulk 
drugs, drug intermediates, chemicals, and pharmaceutical formulations in the form of 
tablets, capsules and orals. Some Important facts about the Pharmaceutical Industry in 
India worth mentioning are: 
 Size of India’s pharmaceutical market is US$4.9 billion (2003) in sales and US 
$3.8 billion in exports. This constitutes about 1% of the global pharmaceutical 
sales and about 10% of the total generics market in the world. In value terms, 
India is the 14th largest market in the world and continues to show satisfactory 
progress in terms of infrastructure development, technology base and product use. 
 In volume terms, India’s share is around 8% and is the 4th largest after USA, 
Japan, and China and in value terms it is 13th largest. 
 India is among the top 5 bulk drugs manufacturers of the world. India has the 
largest number of US Food and Drug Administration (FDA) approved 
manufacturing facilities outside USA. It also has the largest number of Drug 
Master Files (DMFs) filed which gives it access to the high growth generic bulk 
drugs market. 
 India exported drugs worth US$3.2 billion to more than 65 countries. India is the 
14th largest exporter of drugs in the world. 
 The Indian pharmaceutical market has been forecast to grow to as much as US$ 
25 billion by 2010 as per Organisation of Pharmaceuti al Producers of India 
(OPPI) estimates. However, Espicom’s market projections forecast more modest 
but stable annual market growth of around 7.2 per cent, putting the market at US$ 
11.6 billion by 2009. 
  The market has been growing between 6-8 per cent over the last two years, 
primarily driven by new launches and to some extent by volumes. 
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In the last two years, more than 3,900 new products (largely branded generics) have been 
launched in India, contributing about US$ 355.6 million (million) worth of market value. 
While the Indian pharmaceuticals majors launched more than ten products per year, 
global MNCs averaged one or two annually. In 2005, Indian companies controlled 70 per 
cent of the domestic market. * 
 




Temporal Progress Of The Pharmaceuticals Industry 
 
Year Status 
1950s Formulations Mostly imported 
MNC dominance 
1960s Formulations Domestic endeavor 



















minimal imports (< 
2%) 
Self reliant (exports 
> imports) 
                   Source-PRDC Reports 
 
The table above clearly depicts the growth of the Indian Pharmaceutical Industry from an 
import dominated one to one which was self-reliant. 
 
                                                
* Chaudhuri Sudip (2005) Box 2.1 page-51 and www.ibef.org 
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Table 4 
















Capital Investment 140 500 1200 1840 2150 2500.00 3200.00 
Formulations 150 1200 7935 12068 13878 15960.00 18750.00 Production  
  Bulk Drugs 18 240 1518 2623 3148 3777.00 5113.00 
Import 8.20 112.54  2868.00 3128.00 3441.00 4267.00 
Export 3.05 46.38 2184 5353.00 5959.00 6631.00 7980.00 
R & D Expenditure 3 14.75 140 220.00 260.00 320.00 560.00 
Source-PRDC Reports 
 
Overall scenario as deduced from this chart is not very encouraging in terms of all the 
vital parameters like Capital Investment; Production f both Formulations and Bulk 
Drugs, Import, Export and R&D Expenditure post TRIPS. R&D Expenditure is 6% of 
sales. If we compare the figures of ’80-81 to ’94-’5 and ’94-’95 to ’05-’06,  
On the production side,  
From ’80-81 to ’94-95,the increase in formulations has been approximately 6.5 times and 
for bulk drugs, it is almost 7 times. But the increas  from ’94-’95 to ’05-’06 has been 2 
and 2.5 respectively for formulations and bulk drugs. 
Regarding Exports: 
From ’80-’81 to ’94-’95 there has been a 50 times increase but in the later period, i.e, 
from ’94-’95 to ’05-’06, the increase has merely been by 4 times. 
On the R&D front : 
From ’80-81 to ’94-95, it has shown a ten times increase but from ’94-’95 to ’05-’06, the 
increase is not even 4 times. 
 
Table 5 
Top Countries Of Exports Of Indian Pharmaceuticals in 2004-2005 (Rs.Crores): 
 
Name of Country 2004-05 Name of Country 2004-05 
USA 772 Italy 151 
Russia 593 Spain 229 
Germany 425 Nepal 223 
Hong Kong 556 Sri Lanka 224 
Nigeria 558 Japan 220 
U.K. 357 Thailand 218 
Brazil 363 China 237 
Singapore 345 Italy 151 
Netherlands 219 Spain 229 
Iran 280 Nepal 223 
Brazil 363 Sri Lanka 224 
Vietnam 241 Japan 220 
China 237 Thailand 218 
Vietnam 241   
Source-pharmainfo.net 
 
The table above indicates that India still controls a ubstantial share in the world market 
with US topping the list. The Indian government-backed Basic Chemicals, 
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Pharmaceuticals and Cosmetics Export Council, CHEMIXCIL, set an export target of Rs 
610,000 million (US$13.46 billion) by 2006-07 and opp sed formation of 
PHARMEXCIL, saying it could adversely affect India's drugs export. 
  
7. Impact of Product Patents On The Pharmaceutical Sector in India  
When we are talking about the implications of New IPR Regime on pharmaceuticals, 
then it is worthwhile to discuss three categories of drugs: 
 
Old drugs-these implies those drugs which are already off patent when the new IPR 
Regime came into being. 
New drugs which had some patent life left when TRIPS came into being: the most 
prominent example in this group would be the anti retroviral drugs for HIV/AIDS. 
Future drugs-these implies those set of drugs which are yet to be researched upon and 
discovered. 
 
The impact of Product Patent on these aspects have been studied: 
 
7.1 Affordability and Accessibility of Medicines  
 
The impact of TRIPS on pharmaceutical industry in India has been a source of debate 
especially that related to the accessibility and affordability of medicines. India is a major 
source of supply of the world’s generic medicines; it exports 66.7% of its products to 
developing countries The prices of drugs in India are in fact much lower than the prices 
in other countries like Pakistan, U.K. and U.S.A., where product patents are in force. For 
illustrations Ranitidine is sold by Glaxo in India at Rs. 7.20. The same product is sold by 
the same company in Pakistan at Rs. 65 and in the U.S.A. at Rs. 545. Similarly, the anti-
viral drug Aciclovir costs Rs. 33.75 in India while the same drug is sold in Pakistan at Rs. 
363. 
  
Here, I deal with two cases which indicates that post TRIPS, medicines may become 
unaffordable: 
  
Scenario pertaining to AIDS (Acquired Immuno-Deficiency Syndrome): 
AIDS is the most deadly infectious disease in the world today, which currently has no 
cure. But antiretroviral drugs (ARVs) are available for the virus HIV; which prevent the 
outbreak of AIDS. These ARVs have changed the very face of the disease from a fatal 
disease to a more manageable one in the developed countries like USA and Europe, 
where the people can afford it. But, if we take a look at the developing countries, the 
scenario is not very encouraging.  
Here, the case of Sub Saharan Africa is worth mentioning: GlaxoSmithKline (GSK) and 
Boehringer Ingelheim (BI), the two pharmaceutical gi nts involved in the case, between 
them hold the patents for the three antiretrovirals that make up the most commonly 
prescribed treatment for AIDS in Africa: AZT and lamivudine (GSK), and nevirapine 
(BI). A court case had been going on for a year in South Africa, pitting pharmaceutical 
companies against anti-AIDS campaigners. On 9 December 2003,it ended in the signing 
of a historic agreement between the two parties, opening the gates for generic anti-AIDS 
medicine to be made available across sub-Saharan Africa. Under the new agreements, 
producers of generic medicines will swiftly be granted licences to make and distribute 
these three compounds, subject to “reasonable” conditi s - royalties payable to the 
patent-holders will not exceed 5% of the net sale price. These licenses will be 
“voluntary”, which saves the pharmaceutical companies the humiliation of having states 
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issue decrees or pass requisition laws in the form f “compulsory” licenses, and should 
mean the medicines are made available to patients more quickly. The agreements also 
provide for the producers of generic medicines to make, export, market and distribute 
their versions of the compounds in the 47 other countries of sub-Saharan Africa. Generic 
treatments should be available at $140 per patient p r year, when in those days brand 
name medicines cost $10,400 a year. 
 
Currently, of the 6 million people who urgently need ARV therapy in developing 
countries to survive, fewer than 8% are receiving it. (WHO and UNAIDS 2003,pp. 3-4). 
MNCs have been accused of taking advantage of their patent rights to charge exorbitant 
prices for the AIDS drugs still under patents and depriving the poor in economically 
backward countries to avail of the treatment available (Dutfield 2003, p.29). Effective 
antiretroviral (ARV) treatment (triple therapy-stavudine+lamivudine+nevirapine) to 
combat the disease can cost more than US$10,000 (before the introduction of generics by 
India) annually per patient; At that price, it would cost the developing countries like 
Kenya and Zambia more than their national income to provide treatment thus making it 
almost impossible to treat all patients.  
 
Generic competition fueled by Indian production has been largely responsible for 
reducing the prices of antiretrovirals by as much as 98%.There has been a change in this 
pricing from September 2000, when Cipla, a generic company from India, offered to sell 
the triple therapy at US$ 350 (per year). This result d in a crash down of prices. The 
originator company had no other way out than to reduc  the price in the market so as to 
stay competitive. The prices scaled down to US $931 by January 2001 and then further 
down to US$ 727 by March 2001.Since then, other generic companies from India have 
made their entrance into this ARV market, further pulling down the prices. From April 
2003, the triple therapy is available from Hetero at US$ 201 against the originator 
company’s price of US$ 727. (MSF 2003a). The AIDS pandemic has clearly showed the 
negative impact of implementing the product patent system.  
 
The generic production of medicines, both finished an  raw materials form have helped 
in moving the treatment scale up in sub-Saharan Africa, South America, and Southern 
and Southeast Asia. But, generic production only of older, pre-1995 generic versions of 
medicines is not enough to satisfy the treatment needs of people in developing countries. 
Now, when India adopts the new IPR regime, then that will prevent generic competition 
for newer, more expensive “second-line” AIDS medicines which implies prices of newer 
“second-line” antiretroviral treatments will simply be out of reach of the people residing 
in developing countries and requiring them badly. These are precisely the medicines that 
will be considered for patent protection in India. These medicines include 
GlaxoSmithKline’s Combivir (zidovudine/lamivudine fixed-dose combination), which is 
widely used in generic form in India and in African countries, Gilead’s tenofovir (TDF), 
Abbott’s Kaletra, and other important antiretrovirals. 20-year monopolies will drive up 
the price of treatment in India and in hundreds of importing countries—the world’s 
source of supply of generic HIV medicines will essentially disappear. A recent case study 
by a World Bank economist [Chaudhuri, S., et al. “Estimating the Effects of Global 
Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India.” December 
1, 2004 (Working paper)] estimates that the cost to consumers in India alone of India’s 
Patents Act amendments will be untenable.  
 
Anti Leukemia Drug-Gleevec: 
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Now, let us deal with the life saving anti - leukemia drug Gleevec (Imatinib mesylate). 
Imatinib mesylate was once knows as STI571 but is now sold by the Swiss 
Pharmaceutical giant, Novartis as "Gleevec" in the United States and as "Glivec" 
elsewhere. It is FDA-approved for two rare forms of cancer: chronic myeloid leukemia 
(CML) and gastrointestinal stromal tumors (GIST). Gleevec, caused tremendous public 
outcry as prices rose in India from Rs.10, 000 to 1.2. lakhs per month due to “exclusive 
marketing rights” (EMRs) given to Novartis by the government during Nov 11, 2003, 
which rendered treatment unaffordable for majority of the patients.It is said that the 
generics companies like Sun, Ranbaxy, Cipla ,Hetero, Torrent, and Emcure were forced 
to withdraw their generics out of the market when Novartis was given the EMRs- because 
an EMR gives Novartis the right to be the only company in the country legitimately 
marketing the drug for a period of time.. 
 
The generics companies had even stopped production anticipating that Novartis would 
receive the product patent. Novartis has taken a leg l recourse to stop Indian Companies 
from making and marketing the copied versions of the drug. Natco Pharma, a Hyderabad 
based Pharmaceuticals Company, which launched a generic version of Gleevac under the 
brand `Veenat', had challenged the grant of EMRs to Novartis. According to the Natco 
Pharma Vice-President, Business Development, Mr Rajeev Nannapaneni, under the 
provisions of the Indian Patent Act and Rules, exclusive rights can be granted only in 
respect of patents and applications filed in a convention country after January 1, 1995*. 
"According to the information available, the applicat ons for patents with respect to 
Imatinib Mesylate were filed (by Novartis) prior to1995. In this backdrop Natco feels 
that grant of rights is not correct, and therefore, f els that it has a strong case for 
revocation of the exclusive rights," he said. He also said "Granting of exclusive rights to 
a costly therapy, which prohibits the availability of an equally good medicine at a 
fraction of the cost, is against humanitarian principles. In effect, implementation of the 
exclusive rights would make the drug out of reach for thousands of patients who are 
already on Veenat and consequently, this would mean a death sentence to ill-affordable 
patients." This case is currently pending before the Supreme Court.Vice Chairman, 
Novartis also puts forward his point of social welfare as he says the company had given 
the anti-cancer drug free to about 3,306 patients ad only 45 were actually paying for the 
medicine. "On an average, about 30-odd patients enrol for the fre  cancer drug per 
week," he said,  
 
It seems that the government has started intervening in the Novartis’ market. The 
Government has asked Novartis for market-related data on the drug, the pricing and the 
number of patients who need it. This could be laying the ground for Government 
intervention if the price is found to be too high and if patients have been denied the drug, 
an industry representative said.The Government can allow other local companies to 
produce the same cancer drug and hence bring down its price. The other option before the 
Centre is to fix the price on the drug through some sort of a price-control, said a patent 
attorney.Either way, the government will be able to support the present Patent Ordinance 
and convince Parliament that safeguards are in place to protect the patient. 
  
Subsequently, Novartis had applied for an Indian patent and Natco had filed pre-grant 
opposition petition before the Controller of Patents & Designs, as provided in the 
amended Patents Act and Rules. This coupled with reactions from vigilant patients’ 
                                                
* Natco to challenge grant of exclusive rights to Novartis cancer drug, The Hindu Business line, Thursday, 
Nov, 13,2003. - 
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group and legal bodies forced the Indian Controller of Patents and Designs to reject 
the application for patent by Novartis on Jan 25,206. It had been rejected on the 
ground that the product was a derivative of a known substance-Imatinib Mesylate and as 
per The Patents Act, any salt, polymorph or derivative of known substance is not 
patentable unless such salt, polymorph or other substance shows enhanced efficacy of the 
substance. From Jan 25, 2006, the Indian Patents Office has terminated the exclusive 
marketing rights (EMRs) granted to the company on November 10, 2003 for 
Gleevac on the same grounds as the above. Both the rejection by the Indian Patent Office 
and The Indian Controller of Patents and Designs gave a severe blow to this MNC-
Novartis. 
 
This Gleevac story gives us a key hole view of the status of India under the product 
patent regime.Product patents would give companies a mono poly of 20 years and it is 
really to be seen whether it leads to a shortage of ,or to a rise in prices of the medicines 
For instance, the cost of treatment for Gleevac would have gone up from Rs 12,000 to Rs 
1.2 lakh a month had the patent been okayed. In Pakistan, prices reportedly shot up by 
300 per cent when the patent regime was clamped in 2000. According to IMF economist 
Arvind Subramanian’s 2004 report, which compares Malaysia and India, patents will 
push prices up by anywhere between 20 and 760 per cent. Novartis is the first instance 
where the Government has shown that it will ensure access to life saving drugs at 
affordable prices under the new regime.   
 
The recent case of Natco Pharma launching  its brand Bortenat (Bortezomib) 3.5 mg 
injection used in the treatment of multiple myeloma further strengthens our point 
regarding the difference in price of generic and branded drugs. Bortenat would be the 
first time launch of the Bortezomib generic in the world, besides being introduced in 
India for the first time. This adds another feather to Natco Pharma’s cap after Imatinib 
Mesylate (launched under the brand name VEENAT). Natco has priced Bortenat at Rs 
16,800 as compared with Rs 75,000 of the imported micine. 
 
Irrespective of the competition, because of the socio-welfare implication of the 
pharmaceutical prices, all over the world other than in the US, the prices of medicines are 
subject to government regulations. The Government of India has brought certain essential 
drugs under the price control. The price control alng with the amendment of patent laws 
in early ‘70s resulted in a declining impact on prices leading to medicines becoming 
affordable to the common people. Based on India’s own experience,as mentioned above 
in the Novartis’ case and on a selective comparison of prices of a few drugs in countries 
where product patents is in force, it may be said  that the stronger IPR protection would 
result in increase in the prices of the drugs and thus medicines will be inaccessible and 
unaffordable to common people. 
 
One of the major advantages of the stronger regime is that, it would facilitate access to 
new medical products/new discoveries. Though there is a welfare loss associated with a 
probable price increase but there ought to be some welfare gain due to the introduction of 
new products in India by the MNCs, who presently don’t find interest in introducing new 
drugs due to the weak protection. *It is observed that, though Pakistan also has process 
patent regime, some of the new drugs that were introduced in Pakistan by the MNCs were 
not introduced in India at all even though these MNCs were present in the country. This 
is because the MNCs feared about the competition from the counterfeit products in India, 
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whereas in Pakistan MNCs are stronger than the domestic firms.But it also argued that 
since the new patent regime would either raise the pric s of new drugs to the international 
level or make the Indian population wait until the patent expires and drugs become 
cheaper, they in any case will be consuming old drugs, and the purpose of getting quicker 
access to new drugs will be defeated. So it may be said that actually prices would 
increase without much welfare gains in terms of access to new drugs. 
 
It is also possible that higher prices charged by the MNCs may not really affect the 
consumers because; the research activities undertaken by the MNCs do not pertain to the 
requirement of developing and underdeveloped countries market .9Only 13 of 1373 new 
molecules developed during the last 30 years target dis ases of tropical countries like 
India. Hence it can be said that the percentage of population affected by the price rise 
would be very less. Physicians can also play an important role by prescribing generic 
versions instead of the branded ones, thus helping the common people to get medicines at 
affordable rates. 
 
The negative impact of product patents on prices can be attenuated to a considerable 
extent by the government. The two important instruments available with the government 
to regulate prices thereby protecting the consumers against exploitation through high 
prices are:  
• To use flexibilities provided under TRIPS (for example compulsory licensing, 
parallel imports).  
• To resort to price control, which is not forbidden u der TRIPS. 
The Government has already started focussing on price monitoring of essential drugs. 
This would serve to be a major relief to the pharmaceuticals industry. 
The 14-member committee set up by Union Minister for Chemicals and Petrochemicals 
Ram Vilas Paswan have to study the cost of treatment p r day of the 354 drugs listed in 
the national list of essential medicines (NLEM). And have to deduce whether the prices 
are high enough to warrant government intervention. The committee is also supposed to 
look at the disease profile outlined in the 10th Five-Year Plan to see which drugs a larger 
population is using. The Supreme Court had directed th  government to ensure that drugs 
in the NLEM do not go outside price control. 
 
The drug price control mechanisms prevalent in India are applicable on the patented 
drugs too. However,some economists have a different vi w altogether regarding the view 
that whether the  DPCO( Drug Price Control Order) and price control have at all helped 
the pharmaceutical industry. They are of the view that absence of product patents messes 
up the pharmaceutical sector as it had encouraged piracy and production of sub-standard 
drugs in garages. To quote Dr. Bibek Debroy : 
 
In judging success or failure of India’s pharmaceutical policy, the criterion used for 
evaluation is, thus, important. If the number of producers is an indication, the policy was 
successful, the number of manufacturers having increased to 25,000. Since some of these 
drugs were sub-standard and didn’t involve bearing fixed costs, prices were lower. (With 
competition and better enforcement of standards, the number of manufacturers has now 
dropped to around 9,000. And there is nothing wrong with this.) The effect of these 
policy-induced distortions was to discourage investments and innovation and encourage 
piracy, average R&D expenditure was less than 1 per cent of turnover. (As a result of 
allowing product patents, R&D expenditure has now increased to almost 10 per cent of 
turnover for larger Indian pharmaceutical companies and patents have been obtained, 
not only in India, but also in developed countries, the PCT having helped.) Companies 
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moved away from producing essential drugs to non-essential drugs (mainly because price 
control was exercised on essential drugs by the DPCO while non-essential drugs were 
left to market forces) Sometimes, they moved away from drugs to cosmetics and toiletries. 
Consequently, essential drugs had to be imported, a perverse instance of import-
promoting industrialisation, probably the only country in the world to actually adopt 
such a strategy. Instead of research on drugs relevant for India-specific diseases, there 
was an obsession with cardio-vascular diseases, drugs for which could be pirated. The 
Indian pharmaceutical industry is now in a period of transition, no longer scared of 
intellectual property protection and in a position to tap India’s strengths in human 
resources, science and technology. Policies still suffer from distortions, including 
restrictions on human and animal trials. * 
 
Thus we see that this is a widely debated issue and we will be able to see the actual 
impact, only after a certain time gap.  
 
7.1.1 New Drug Policy: boon to both patients and Inustry 
Chemicals and Fertiliser Minister Ram Vilas Paswan’s acceptance of the pharmaceuticals 
industry’s proposals vis-à-vis the new drug policy, if implemented, would pave way for 
an exciting future for the industry. At the same time, patients would benefit significantly 
from low-cost, high quality drugs as a result of competition in the industry.  
 
After India became IPR compliant, most pharmaceuticals companies suffered heavily 
because of numerous ill-timed policies such as MRP-based excise duty, constant 
reduction of drug prices by the NPPA, regulatory isues, patent-related legal battles 
and unmanageable R&D expenses. Broadening the range of price control would have 
served as a disincentive for this sunrise sector. Research-based pharmaceuticals 
companies hope to be the biggest gainer as they can now focus significantly on 
researching India-specific diseases. The pharmaceuticals industry’s offer is to cap 
generic-generics profits at 50 per cent of the cost.  
 
The new policy would now consist of five main elements: 
 
 There would be a public-private partnership to help poor families.  
 Industry would offer drugs at concessional prices to government-run hospitals.  
 The government, on its part, would promote competition to contain prices.  
 The chemicals ministry would move from cost-based to a price-monitoring system.  
 The ministry would set up a 14-member committee, including 11 members from the 
industry to work on the interim order of the Supreme Court. 
 
Paswan has also announced a Rs 200-crore cancer rehabilitation fund to provide 
free/subsidised drugs. Price control will also be removed for all drugs priced up to Rs 3. 
In addition, he also agreed to push for increasing the healthcare budget from the existing 
0.9 to 3 per cent of GDP. 
 
Both the patients as well as Pharmaceuticals companies will get benefited. Patients can 
now get unbranded generics at rock-bottom prices and the pharmaceuticals companies 
will have full freedom in the R&D area. Cost-based price control is the last bastion of the 
dreaded licence raj. On paper, drug prices are controlled, but in reality, it puts a question 
mark on both the availability and quality of drugs. For instance, over 20 million Indian 
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women and 80 per cent of children suffer from anaemi . Similarly, thousands of flood-
affected people suffer from Leptospirosis. Their sufferings are only further compounded 
due to non-availability of related drugs, due to their being placed under the price control 
system. By capping margins in generics, on one hand,  promoting R&D, on the other, 
the chemicals ministry is sure to kill many birds with one shot. * 
 
7.2 Research and Development  
Indian Pharmaceuticals Industry has basically been a hub for the generics. Consequently 
research has taken a back seat here . R&D was largely concentrated on process 
development for known bulk drugs although through novel and innovative process routes, 
invariably substituting for expensive imported raw materials enhancing the productivity 
and efficiency of the processes, besides research on formulations and known drug 
delivery systems. India’s R&D forte has been in synthetic organic chemistry and process 
development. A few new drugs, using conventional screening techniques, have emerged 
from the Indian R&D, but none of them have been blockbusters.* But after 2005,reverse 
engineering skills will only be useful for manufacturing products going off patent. So 
Indian firms will be forced to go in for product-based research for achieving high 
profitability. Therefore Indian companies such as Ranbaxy,Dr. Reddy’s laboratories 
,Wockhardt, Sun Pharmaceuticals, and Cipla, among others have started to invest in 
product research as opposed to process research. There has been a shift from business- 
driven research to research-driven business. These firms are setting up labs for 
undertaking research on new molecules and are also continuing to hone their reverse 
engineering skills to manufacture drugs going off patent. 
 
Investment in R&D by industry as a whole in India hs been low, only around 0.6% of 
the turnover. In the Indian pharmaceutical industry the average R&D expenditure is 
around 2% of the turnover contributed by around 150companies. The low investment in 
R&D is due to the low levels of profitability and comparatively small size of the 
companies. However, the scenario is now changing. Some pharmaceuticals companies 
now spend nearly 5% of their turnover on R&D. In addition to R&D in industry, 
substantial pharmaceuticals related R&D is carried out in publicly funded research 
organisations, mainly by the laboratories of Council of Scientific & Industrial Research 
(CSIR), Indian Council of Medical Research (ICMR), around 25 universities and a few 
pharmacy colleges. Some of the new R&D units in industry and a few of the publicly 
funded laboratories are equipped with sophisticated laboratory equipment, instruments 
and pilot plant facilities. The R&D manpower is generally highly qualified and proficient 
in conventional techniques of pharmaceutical R&D.  
 
 But Generic Industries will experience a good future as $72-billion worth drugs expected 
to go off patent (between 2006 and 2010). This implies a great boost for the generics 
industry. To maximize profits from their technological expertise, many generic 
companies make it a top priority to be the first to file a generic version with patent 
challenges so that they can enjoy the six-month marketing exclusivity. This strategy can 
bring massive revenues in the short term 
 
To support developments and research of this kind, the Indian government is providing a 
range of tax concessions designed to encourage R&D, including a 10-year tax holiday on 
income arising from R&D. Besides, planning commission earmarked $34 million towards 
drug industry R&D promotion fund for the tenth plan. Moreover, the series of proposed 
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recommendations of the A.R. Mashelkar committee set up by the government regarding 
price liberalization, fiscal incentives and appropriate R&D regulatory framework, would 
be expeditiously implemented to give an impetus to R&D activities.  The aim is to at 
least double the domestic pharmaceutical industry's level of R&D expenditure - which is 
very low by international standards - by 2005. After 2005, there will be wide scope for 
Indian drug companies in the world market, and those that have strong R&D activities as 
well as significant domestic and international busine s will have an edge over others 
The year 1994-95 was the turning point for the industry due to the advent of the WTO. 
The industry has since sought to reorient itself from looking inwards to being a player in 
the global arena. The increased proportion of R&D expenditure to both investment and 
turnover reflects the thrust on R&D by the Indian pharmaceutical industry.                                                            
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882 7.52 383 3.72 19 
Wochhardt 604 7.89 462 6.23 13 
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559 3.90 185 1.63 12 
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182 8.50 175 1.42 4 
J B Chemicals & 
Pharmaceuticals 
69 2.20 50 1.73 2 
Total 10,021 7.73 6726 5.55 218 
Source- Chaudhuri Sudip (2005) table 5.2, pg 161, 
Table 7:R&D Expenditure of Indian Pharmaceutical Companies from 1981-97 to 
2005-06: 





 2001-2002 320.00 
2005-2006 530.00 
                 Source- pharmainfo.net 
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Expenditures by top Pharmaceutical MNCs ,2003 
 
MNC R&D Expenditure,US $ 
billion 
R&D Expenditure as per cent 
of sales 
Pfizer 7.13 17.99 
GlaxoSmithKline 4.54 15.23 
Merck 3.17 9.47 
Johnson&Johnson 4.68 24 
Aventis 3.23 17.01 
AstraZeneca 3.45 18.30 
Novartis 3.07 19.16 
Bristol-Myers Squibb 2.27 15.21 
Wyeth 2.09 16.56 
Eli Lily 2.35 18.68 
Total 35.98 16.63 
Source- Chaudhuri Sudip (2005) table 5.4 page 167 
 
The comparison of the two tables (table 6 and table 8) above clearly indicates the paucity 
of funds at the disposal of the Indian Pharmaceuticals ompanies. The tenth largest MNC 
Eli Lily spent US$2.35 billion as compared to the largest in India, Ranbaxy that spent at 
around US$ 60 million. Thus, we see, India poorly compares with the pharmaceuticals 
giants worldwide in terms of R&D Expenditure incurred. To raise resources R&D Firms 
may consider a variety of options like mergers with o er Indian Firms, collaboration 
with foreign firms, joint ventures with foreign firms in other countries, leveraging the low 
cost home base ,joining R&D consortia centered around Institutes like CDRI, Lucknow 
or IICT and joining industry oriented research organiz tions sharing expensive facilities. 
 
One of the advantages of the new patent regime is the Bolar Provision (discussed earlier), 
which entails a free flow of technical knowhow and knowledge giving a tremendous 
boost to local companies to invest in research. The higher cost of the R&D serves to be 
an effective entry barrier for new firms and hence only firms with large flow of funds are 
capable of any inventive activity. In developing countries, a handful of firms have 
sophisticated R&D facilities and others benefit mainly from the spillovers of the resultant 
R&D. More often small firms shy away from investing in R&D because; financial risk 
involved is too high as there are more possibilities of failure than success. 
 For instance, cost of developing one new drug in the US increased from $54 million in 
1970 to $231 million in 1990. Recent studies indicate that 1 out of 5000 compounds 
synthesized during applied research eventually reaches the market. Other estimates 
indicate that of 100 drugs that enter the clinical testing phase I, about 70 complete phase 
I, 33 complete phase II, and 25-30 clear phase III. Only two-thirds of the drugs that enter 
phase III is ultimately marketed. According to a USFDA report 84 per cent of new drugs 
placed on the market by large US firms during the period 1981-88 had little or no 
potential therapeutic gain over existing drug therapies. Similarly in a study of 775 New 
Chemical Entities introduced in to the world during the period 1975-89, only 95 were 
rated to be truly innovative. * 
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Because of these reasons and due to the protected policy regime, the R&D investment in 
India has been very low and started picking up only i  the mid ‘90s, when TRIPS came 
into effect. . The Indian pharmaceuticals R&D pipeline has been evolving over the years. 
The pipeline is in the early stages and is likely to take two to three years to reach critical 
mass. Of the Rs.1, 800 crores spent on R&D in 1998, 35 per cent belongs to the public 
and joint sector and that of the private sector is about 65 per cent. In spite of the growing 
investment in R&D, R&D as percentage of sales ratio stagnates around 2 per cent. 
Further of the 1261 Department of Science and Technology recognised R&D units, 256 
have spent more than Rs. 1 crore every year. 350 have spent between Rs.25 lakhs and Rs. 
1 crore and the remaining below Rs. 25 lakhs.**  This clearly indicates that most of the 
R&D investment was perhaps directed towards process improvements and adapting the 
technology to local conditions thus resulting in technology spillovers rather than in new 
product developments. For instance, the UK multinatio l Glaxo was faced with several 
local competitors on the first day when its subsidiary marketed its proprietary drug 
Ranitidine in India, because the competitors enabled y the weaker patent regime were 
ready with the indigenous version of Ranitidine. 
 
Table 9 







PHASE 1 PHASE 2 PHASE 3 
Ranbaxy 5 3 2 n.a. 
Dr. Reddy’s 
laboratories 
5 2 1 n.a. 
Wockhardt n.a. n.a. 1 n.a. 
Nicholas 
Piramal 
n.a. n.a. 1 n.a. 
Lupin n.a. n.a. 2 n.a. 
Orchid  2 1 n.a. n.a. 
Torrent 19 n.a. n.a. n.a. 
Glenmark 1 1 n.a. n.a. 
Dabur 29 1 1 n.a. 




The positive sides of undertaking research in India are R&D costs in India are much less 
than that in the developed world and both New Drug Discovery Research and New Drug 
Delivery Systems programmes can be market conducted at very competitive rates. India 
also has a well-established network of research labs and a strong pool of skilled scientific 
personnel. The success of a few companies in this area (table shown below) has also 
demonstrated to the rest of the industry that investm nts in R&D can yield handsome 
returns. The Investigational New Drug stage may cost $100 to 150 million overseas but 
costs only around Rs.40 to 60 crores in India, says the Mashelkar Committee report. The 
report adds that while clinical trials cost approximately $300 to 350 million abroad, they 
cost about Rs.100 crore in India. 
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On the negative side, R&D activities in India are adversely impacted by lack of financial 
resources which compels them to focus mainly on drug delivery systems and similar 
molecules; inadequate regulatory framework which relates to a host of issues such as lab-
testing of animals; outdated and inadequate patent office; long delays in getting required 
approvals for conducting trials etc. Yet, to stay competitive in the future (i.e. post 
TRIPS), the companies will have to increasingly refocus and invest heavily in R&D.  
 
Most Indian companies realize that it will be difficult for them to commercialize their 
discoveries on an international basis on their own as they are unable to perform a start to 
finish model in NCE research, due to scarcity of skills and required funds: says Annual 
Report, 2001-02 of Glenmark Pharmaceuticals . Therefore they are entering into 
licensing deals i.e., to develop new molecules and license out the molecules to the MNCs 
in the early phase of clinical development and strategic alliances with international 
companies. Dr. Reddy’s Laboratories initiated this licensing out of new molecules. 
Ranbaxy, Torrent and Glenmark had followed suit. 
 
India’s inherent strengths (low-cost manufacturing, strong re-engineering skills, talented 
human resource at low cost) makes it a lucrative outsourcing destination for global 
players and also helps to tap international markets through contract manufacturing and 
conducting collaborative research. An alliance with an Indian firm is expected to aid 
innovator companies to capitalise on the low-cost base for collaborative and contract 
research and manufacturing, while generic players will benefit by enhancing their first-to-
file position, expanding their portfolio and reducing their costs. Although the outsourcing 
of the drug discovery process is gradually gaining momentum, research-outsourcing 
demand in India will come chiefly from conducting/supporting clinical trials. The 
availability of a large  patient population (in tha, they have not undergone treatment) and 
well trained medical professionals at significantly low costs has made India an attractive 
destination for conducting global clinical trials. At present, 90 per cent of the trials 
conducted in India are bio-equivalence studies for filing abbreviated new drug 
applications (ANDA) with the US FDA. Only 10 per cent of the studies are actual clinical 
trials aimed at the development of NMEs. However, this ratio is expected to change in 
favour of clinical trials for NMEs by 2009. 
Some deals finalised for clinical trials are listed below: 
• Eli Lilly has 17 clinical research projects in 40hospitals across India. 
• Pfizer has picked 6 cities in northeast India for clinical trials for an anti-malaria drug. 
• Roche has set up clinical trial sites for lung cancer drugs in India.* 
 
Table 10 
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Age Breaker 2004 In Progress 
 
Source: CRIS INFAC 
n.a-not available 
 
India was estimated to account for around 7 per cent of the global outsourcing market for 
bulk drugs in 2004-05.By 2009-10, India is expected to account for 10-15 per cent of the 
global bulk drug outsourcing market, which is expected to surge at a compounded rate of 
22.2 per cent, from Rs 80.7 billion ($1.8 billion) i  2004-05 to Rs 220.1 billion ($4.9 
billion) in 2009-10. However, on the domestic front, outsourcing demand for bulk drugs 
is expected to slow down in the short-to medium term after which demand (as a 
percentage of apparent domestic consumption of formulations) is expected to pick up 
marginally to show an overall growth of 1.6 per cent between 2004-05 and 2009-10 to Rs 
12.2 billion. The overall bulk drug market is expected to surge at a compounded rate of 
20.4 per cent to Rs 232 billion in 2009-10.** 
Table 11: Overall bulk drug demand outlook 
  2000-01 2004-05 (E) 2009-10 (P) CAGR (2004-05 to 2009-10) 
Domestic outsourcing 6,045 11,289 12,221 1.6 
Exports/Contract 
manufacturing 
39,285 80,664 220,091 22.2 
Total market 45,330 91,953 232,312 20.4 
E: Estimated; P: Projected     
Source: CRIS INFAC 
This way their development costs will get shared an returns will accrue faster. Yet, there 
is another part to this story, which is a case of wrry. This policy of licensing out may 
shift the focus of research in the LDCs as major R&D firms may be more involved in 
drug discovery that addresses the global diseases and neglect the research that is more 
relevant for the LDCs. In this context the words of Amit Sen Gupta, of the National 
Working Group on Patent Laws, is worth adding: “I think for me it’s frightening that 
ten or twelve people today are deciding what are thkind of drugs that need to be 
researched because clearly those drugs are being researched not because of the health 
needs but based on how much profits they can bring . That’s why you have research 
money going into drugs for baldness or Viagra but the last drug for tuberculosis was 
30 years back. When you deny people cars or washing machines they don’t die, when 
you deny people drugs they die and they die in millions.” 
It is apparent that Indian pharmaceutical R&D has several scientific-techno-economic 
advantages that by far outweigh the few inherent weakn sses. The opportunities are 
appealing and attractive and the threats manageable. Thus if the proper policy support 
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and direction is given, the industry can carve out a niche for itself in the global market 
place. 
7.3 Investment Strategies 
7.3.1Foreign Direct Investment (FDI): 
Foreign Direct Investment creates a long-standing association and commitment of one 
economy over the other.The weak protection of the IPRs in the Pharmaceutical sector in 
India served as a disincentive for FDI mainly by the countries like US,Japan and 
Germany. However, with the change in scenario, that is post TRIPS, there has been an 
increase in FDI. 
This graph below shows the FDI in the pharmaceuticals sector from the year 1996-
2000.It shows a steady increase. 
Graph-2 
March  2005
FDI in the Pharma Sector
FDI in the Pharmaceutical Sector from 1996 - 2000
* 
If the IPR is strengthened, it will lead to an increase in foreign direct investment (FDI) in 
R&D, direct manufacturing or joint ventures. However, this inference cannot be 
definitely concluded since IPR is only one of the factors in attracting FDI. FDI flows 
depend on skills availability, technology status, R&D capacity, enterprise level 
competence and institutional and other supporting technological infrastructure. 
According to US Under Secretary of Commerce for Inter ational Trade Franklin L Lavin 
"India's FDI policy should be more flexible to allow more foreign equity and ensure 
level-playing field for foreign and domestic companies," Highlighting the FDI flows to 
countries with allegedly low levels of IPR protection, Correa observes that the perceived 
inadequacies of intellectual property protection did not hinder FDI inflows in global 
terms. Thus FDI increased substantially in Brazil since 1970 until the debt crisis exploded 
                                                
* www.ibef.org 
 23 
in 1985, while in Thailand FDI boomed during the eight es. In contrast developing 
countries that had adopted stronger protection havenot received significant FDI inflows. 
He further observes that FDI in the pharmaceutical industry outpaced FDI in most other 
sectors in Brazil after patent protection for medicines was abolished in that country. In 
Italy after the introduction of process patent protection in 1978, FDI increased.* Hence, it 
appears that patent production does not have significa t impact on FDI. 
From August 1991 to May 2006, FDI inflows received are to the tune of Rs. 43217.70, 
amounting to $1009.63 and constitute 3.07% of the total FDI inflows in the country. **  
Table-12: FDI inflow into pharmaceutical sector from 2002-03 to 2006-07 (Rs. In crore 
and $ in millions in brackets: 































Source-Dept. of Industrial Policy and Promotion 
Though India is taking a well set of measures to improve the flow of FDI it is not able to 
wipe the ambiguity in the minds of investors. According to Boston Consultancy Group 
(BCG), FDI investors perceive a high degree of uncertainty in India. This includes 
political and administrative uncertainty, legal delays and bureaucratic delays. The 
positive image of India needs to be improved.  
TRIPS had led us to believe that Patent protection in I dia will stimulate investment into 
R&D that will benefit Indian consumers and will reward India with increased foreign 
investment. But in reality Profits generated by sales in India will not be large enough to 
affect the R&D agenda of multinational pharmaceutical companies. A recent case study 
estimates the returns to the pharmaceutical industry af er implementation of a product 
patent regime in India to be only $53 million per yar. According to the recent findings of 
an international commission, “Integrating Intellectual Property Rights and 
Development Policy.” Final Report of the UK Commisson on Intellectual Property 
Rights. September 2002.”  “The evidence suggests that the IP system hardly pla s any 
role in stimulating research on diseases particularly prevalent in developing countries, 
except for those diseases where there is also a substantial market in the developed world, 
Nor it is likely that the globalization of IP protection will lead to greater investment by 
the private sector for the development of treatments for diseases that primarily affect 
developing countries.” 
 
The bad news for India is that 90% of pharmaceutical executives, from North America, 
Europe, Asia and India have voted for China over India (survey by Bain and Company) 
for low –cost drug manufacturing. Regarding the factors affecting the Pharmaceuticals 
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Industry in India, 56% have voted for the IPRs, 52% for parallel trade or grey market 
imports and 46%, the regulatory uncertainty. But, the brighter side of the survey is that 
India has been foreseen to be much better five years from now. Indian market has also 
been characterized as attractive by 35% as in 2006 and 58% expect it to be attractive by 
2011.* 
 
Bain has recommended that Indian Pharma companies should strive for low cost 
leadership in their core generic drug businesses through a rigorous focus on operating 
efficiency and begin to invest in innovation.The India  government should create the 
right business environment for both MNcs and Indian companies by addressing key 
concerns over IP protection, parallel trade and regulatory uncertainty.MNCs should 
start investing now to take advantage of the domestic Indian market but it should be done 
in a measured way while pressing for regulatory refo ms. 
 
7.3.2 Mergers and Acquisitions: 
 
The health-care costs are rising worldwide. Leading companies are merging. Strategic 
alliances and collaborations are taking place in order to meet the increasing R&D 
budgetary requirement that exceeds a billion dollars each for many leading global 
pharmaceuticals players As for India, The generic nature enables the pharmaceutical 
companies to enjoy a cost advantage, thus encouraging them to acquire firms abroad. 
These industries are enjoying the foreign face, which some times helps them to acquire 
some other firms and also benefit with brand equity. 
 
The increasing number of local pharmaceuticals multinationals points to India’s strong 
foothold at a global level. The number has gone up to 12 in 2004-05 and 2005-06 owing 
to rising global buyouts and organic expansion. The new entrants are Dr Reddy's 
Laboratories, Wockhardt, Nicholas Piramal, Sun Pharmaceuticals, Glenmark, Orchid 
Chemicals and Pharmaceuticals, Unichem, Torrent Pharmaceuticals, Cadila Healthcare, 
Lupin and Cadila Pharma. The drug sector had only oe Indian multinational, Ranbaxy 
Laboratories, till 2004.* 
 
Table-13 
Pharmaceutical companies and their subsidiaries 
 
Rank Company Name Subsidiaries in Number of countries (global 
subsidiaries) 
1 Ranbaxy Laboratories 25 
2 Dr. Reddy’s 
Laboratories 
10 
3 Sun pharmaceuticals 8 
4 Wockhardt 7 
Source-Business Standard,Aug 24, 2006  
 
On the M&A front, the year 2005 had been quite significant for the domestic 
pharmaceutical sector. Although, most of the overseas subsidiaries were set up through 
global expansions, the number of global acquisitions has also increased substantially in 
the last two to three years. Since the Indian companies have adopted new strategy of 
                                                
* China preferred choice for Pharma cos.-study, The Hindu,,Aug 06,2006 
* Unnikrishnan H C,Local pharma players storm multinational bastion , Business Standard August 24, 
2006- 
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acquiring medium and small companies overseas, the estimate worth of global 
acquisitions in the last three years is more than Rs 4,500 crore.  
 
Table-14  





Acquirer Type Total Value 












Buyout 324 2005 
Docpharma, 
Belgium 





Acquisition 50 2005 
Avecia Pharma Nicholas 
Piramal 
Acquisition 16.25 2005 
RPG Aventis Ranbaxy Buyout 80 2005 
Mexican API 
unit of Roche 

















Acquisition 60 2006 
GSK generic 
drug unit in 
Spain 





Dishman Acquisition Not known 2005 
IO3S 
Switzerland 
Dishman Acquisition Not known 2006 
Source-Business Standard, August 24,2006 and compiled data from various websites 
n.a-not available 
 
Analysts expect the M&A activity to intensify, as the consolidation will play a crucial 
role in future. The size and economic scale does matter in the highly competitive 
environment. During the last two years, major acquisitions were engaged in marketing, 
but some domestic companies had invested in building manufacturing capacities in 
developed markets. Indian companies have already installed plants in the US, Europe, 
Brazil, Russia and China. Analysts pointed out that the medium scale domestic 
companies will first strengthen their marketing activity in these countries and then they 
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will set up manufacturing units to improve the supply chain. At the same time, the 
companies are also setting up capacities in the domestic locations to explore the generic 
boom. 
 
The domestic pharmaceutical companies have created their brand image in the regulated 
markets, which is evident form the success of the fund raising initiatives through 
securities and commercial papers. Several companies issued foreign currency convertible 
bonds to part-finance their expansion and acquisitions. With strong financials, those 
issues received overwhelming response from foreign investors. 
 
8. Future of The Pharmaceutical Industry in India 
The strength of the Indian pharmaceutical industry is in reverse engineering. Such units 
by utilising the provisions under compulsory licensing, parallel imports and exceptions 
to exclusive marketing rights under the TRIPS agreement should aim at producing the 
generic version of the patented product and those that are nearing patent expiry. Such 
firms should also be engaged in research leading to ew drug delivery mechanisms and in 
identifying new uses of existing drugs. In this context, it is also essential to protect the 
innovations that have been introduced by the technology spillovers. Further more, some 
of the new sources of NCEs could be plants, microbes, fungi, insects and various venoms. 
The extracts from these material sources must continue to form a major source of entirely 
novel structures. 
It is true that the New WTO regime has stimulated the R&D investment in India, but it is 
equally true that even the largest Indian companies ar  no match for the pharmaceutical 
giants in the world in terms of size, scale of operation and R&D budgets as of now and it 
will require some more years to make it big in the field of new drug discoveries. Some of 
the big units have started strengthening their R&D (as mentioned above) and have also 
filed number of applications for DMFs (drug master files). Companies such as Ranbaxy 
Laboratories, Nicholas Piramal, Cipla, Glenmark Pharma and many others have been 
ramping up their R&D programmes in a big way and plan to increase their R&D 
expenditure to 7-10 per cent of the sales revenues from the present industry average of 2-
3 per cent Yet, India can harness certain other opportunities available to it right now. 
Enlisted are some of the ways that can help India to have a considerable impact in the 
global arena:  
a) Most cost-effective manufacturers of generic drugs. The global market for 
generic drugs in 2005 is estimated at $36 billion and should grow further with the 
impending expiry of patents on drug sales worth over $50 billion. 
b) Outsourcing of R&D and manufacturing. (Discussed in detail above) 
c) Investment on manufacturing and production capacities (specially foreign 
approved ones). 
d) Economising on scarce R&D resources by going in for me gers and consolidation.  
e) To rectify the bottlenecks contributing to the widening gap between the proposed 
FDI and the actual FDI. 
f) To figure out where the Indian firms are lacking by observing the difference 
between the number of patents filed and the patents granted. 
g) The governing body may define a list of essential medicines, such as antiretroviral 
(ARV) agents, that would be subject to somewhat more relaxed patent protection 
compared to other drugs. 
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h) Internal networking and co-ordination amongst different constituents of 
innovation chain to bring down the time and costs of new drug discovery and its 
introduction in the market place. 
In this respect, the SWOT Analysis (Strengths, Weakn sses, Opportunities, Threats) 
of the Indian Pharmaceuticals Industry is worth mentioning. The analysis points out 
to India’s prospect to come out as a global player: 
Table 15: SWOT Analysis 
STRENGTHS OPPURTUNITIES 
Strong manufacturing base Outsourcing and networking. 
Rich base of traditional knowledge Potential for clini al research and initiating 
clinical trials. 
Well developed engineering base Contract manufacturing arrangements with 
MNCs 
Experience in successful process development Potential for developing India as a centre for 
international clinical trials 
Access to pool of highly trained manpower 
with low costs. 
Significant export potential. 
WEAKNESS THREATS  
Low investments in innovative R&D due to 
paucity of resources. 
Inability to cope-up with the rapidly changing 
new drug discovery technologies and processes 
at the global level 
Lack of strong linkages between industry and 
academia 
Product patent regime poses serious challenge 
to domestic industry unless it invests in 
research and development 
Lack of resources to compete with MNCs for 
New Drug Discovery, Research and 
commercialization of molecules on a 
worldwide basis. 
R&D efforts of Indian pharmaceutical 
companies hampered by lack of enabling 
regulatory requirement. 
Inadequate regulatory standards. Export effort hampered by procedural hurdles 
in India as well as non-tariff barriers imposed 
abroad 
Inadequate trained manpower in 
emerging areas. 
Lowering of Tariff Protection. 
Source-PRDC Report 
The three tropical diseases or rather the diseases prevailing mostly in the developing 
countries-AIDS, Tuberculosis and Malaria will be giving Indian Pharmaceuticals a $2 
billion opportunity each year. WHO, UNO to fight these diseases, is pooling funds worth 
$4 billion yearly till 2015. As a result, campaigns like Global Fund for AIDS, TB and 
Malaria, President Bush’s Emergency Plan for AIDS Relief (PEPFAR), Stop TB 
Partnership and Roll Back Malaria are being affected. Indian Companies stands to benefit 
as they are in a position to capture 50% of the market owing to their cost advantage, 
expertise in anti-infectives segment and experience i  procuring regulatory approvals. 
Moreover, India having the highest number of USFDA approved plants outside USA and 
having the same disease pattern gives them an edge over their US and European 
counterparts in generics (anti-retrovirals for AIDS and anti-infectives for treating TB and 
malaria — are roughly 20 to 30 per cent cheaper to the generic drugs supplied by the US 
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and European companies). It is predicted that all the companies who are in this anti 
infectives segment would join the bandwagon of suppliers for such sponsored products. 
The total burden of these three diseases is $23 billion annually (including prevention, 
diagnosis, treatment and care), as estimated by various global agencies. During 2006-
2010 period, AIDS programmes alone would receive funds worth $3 billion, tuberculosis 
about $450 million and malaria another $768 million, each year. Roughly 50 per cent of 
it could accrue to India. *The challenges before the Indian company now is to make 
investments in procuring WHO approvals, attain efficiencies in supply chain 
management to ensure timely delivery of drugs as well as maintain the cost advantage. 
The Human Development Report of 1999 has highlighted that there is a tremendous 
concern about the control of knowledge as tighter intellectual property rights raise price 
of technology transfer and increase the technological gap and block the developing 
countries out of dynamic knowledge sector. On the ot r hand, the major pharmaceutical 
companies argue that compliance of the provisions of TRIPS would stimulate transfer of 
technology, encourage foreign direct investment, strengthen R&D investment and also 
ensure early introduction of new products in developing countries. These arguments are 
invariably backed by data on increased FDI in some countries where stringent IPRs were 
introduced. Whereas these claims and counter claims could be debated, the Indian model 
has to be based on providing medicines at affordable prices to the needy Indian 
population on one hand and also leveraging the Indian intellectual prowess on the other, 
through which India could create its own intellectual property. 
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